Business Context and Reporting Period
This Form 8-K is a current report filed by Silexion Therapeutics Corp on December 16, 2024, covering events occurring between December 10, 2024, and December 13, 2024. The company is incorporated in the Cayman Islands with principal executive offices in Ramat-Gan, Israel, and its ordinary shares and warrants trade on The Nasdaq Stock Market LLC under the symbols SLXN and SLXNW, respectively.
Key Financial Metrics
This filing is a report of corporate governance and listing compliance events. It does not provide financial data regarding revenue, profit, cash flow, margins, debt, or liquidity. No financial statements or metrics are included in this document.
Material Changes
The filing reports the successful remediation of two Nasdaq listing deficiencies:
- Minimum Bid Price Compliance: On December 13, 2024, Nasdaq confirmed the company regained compliance with Listing Rule 5450(a)(1). The closing bid price for ordinary shares remained at or above $1.00 for 10 consecutive business days (November 29 to December 12, 2024), resolving a deficiency previously notified on October 29, 2024.
- Audit Committee Compliance: On December 10, 2024, Nasdaq confirmed the company regained compliance with Listing Rule 5605(c)(2). This was achieved through the appointment of Professor Amnon Peled to the board of directors and audit committee, resolving a deficiency regarding the required number of qualified committee members notified on November 20, 2024.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding business operations. The primary risk addressed was the potential delisting due to non-compliance with Nasdaq rules, which has now been mitigated. The company was previously granted a cure period until April 28, 2025, for the bid price deficiency and a cure period ending by September 16, 2025, for the audit committee deficiency; both have been resolved ahead of these deadlines.
Investor Verification Checklist
- Verify the current trading status of SLXN and SLXNW on Nasdaq to confirm continued listing.
- Confirm the official appointment of Professor Amnon Peled to the Audit Committee in subsequent corporate filings.
- Monitor future 8-K filings for any recurrence of bid price deficiencies below the $1.00 threshold.
- Review the company's most recent 10-K or 10-Q for actual financial performance data, as this 8-K contains none.